Clinical trials: Personalized Cancer Vaccine
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local
- Trial name
- NCT07898124
- Testing
- TMV Vaccine, Toripalimab-tpzi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Metaclipse Therapeutics Corporation
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma
- Trial name
- NCT05098210
- Testing
- Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer Female
Personalized Vaccine for TNBC Immunotherapy
Due to their genetic instability, breast tumors that do not express receptors for Estrogens, Progestagens or amplify the Her2 / neu oncogene [called triple-negative breast cancer (TNBC)] and other tumors such as melanoma…
- Trial name
- TEBICA003 TNBC (NCT06195618)
- Testing
- Peptide (neoantigen) pulsed autologous Dendritic cell
- Where
- Colombia
- Volunteers
- 8 people
- Sponsor
- Universidad Nacional de Colombia
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification
Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer
Microlyvaq™ is a first-line, non-randomized, two-arm clinical trial in advanced non-small cell lung cancer (NSCLC). In both arms, patients receive a personalized multi-epitope vaccine (Microlyvaq™) on top of standard-of-care…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- Microlyvaq™ (NCT07285434)
- Testing
- Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic)
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Melanoma, Colon Cancer
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Background: Exome sequencing can identify certain gene mutations in a person's tumor. This can then be used to create cancer treatments.
- Conditions
- Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- NCT03480152
- Testing
- National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
- Trial name
- NCT03568058
- Testing
- Personalized Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Aaron Miller
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of Personalized Neoantigen Cancer Vaccines
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03794128
- Testing
- Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- Gritstone bio, Inc.
Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer
Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that…
- Trial name
- NCT03871205
- Testing
- Neoantigen loaded DC vaccine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen People's Hospital
Non Small Cell Lung Cancer, Neoepitopes
AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.
The goal of the project is to develop and validate A.I.mmune technology. It performs complex analyses of patients' tumor and immune system state using data derived from next-generation sequencing of tumor and healthy tissue to…
- Conditions
- Non Small Cell Lung Cancer, Neoepitopes, Neoantigens, Immunotherapy
- Trial name
- NCT04145232
- Testing
- Collection of biopsy (FFPE), blood (PBMC) and stool
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Ardigen
Melanoma Stage IV, Unresectable Melanoma
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab…
- Trial name
- NCT05309421
- Testing
- EVX-01, Pembrolizumab 25 MG/ML
- Where
- 4 sites in Australia, Italy
- Volunteers
- 17 people
- Sponsor
- Evaxion Biotech A/S
NSCLC
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
Brief Summary: This study is an open, prospective, exploratory clinical trial designed to evaluate the safety,ability, immunogenicity, and preliminary efficacy of a personalized neoantigen mRNA vaccine in combination with…
- Trial name
- NCT06735508
- Testing
- mRNA Neoantigen Vaccine, Adebrelimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Provincial People's Hospital
Esophageal Cancer, Non Small Cell Lung Cancer
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung…
- Trial name
- NCT03908671
- Testing
- Personalized mRNA Tumor Vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Stemirna Therapeutics
Solid Tumor
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors
This trial is an investigator-initiated, single-center, open-label, single-arm exploratory study of mRNA personalized neoantigen tumor vaccine in the treatment of advanced solid tumors, including two phases: dose escalation and…
- Trial name
- NCT05359354
- Testing
- Personalized neoantigen tumor vaccine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- YueJuan Cheng
Neoplasms
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms
The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.
- Trial name
- NCT05475106
- Testing
- Neoantigen Peptides
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto de Medicina Regenerativa
Pancreatic Cancer
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.
- Trial name
- NCT04161755
- Testing
- Atezolizumab, RO7198457, mFOLFIRINOX
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of Gastrointestinal Tract
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.
- Trial name
- NCT05153304
- Testing
- personalized vaccine, Nivolumab
- Where
- United States
- Sponsor
- University of California, San Diego
Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric…
- Conditions
- Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Colorectal Adenocarcinoma
- Trial name
- NCT03468244
- Testing
- Personalized mRNA Tumor Vaccine
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changhai Hospital
Glioblastoma
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also…
- Trial name
- NCT02287428
- Testing
- Radiation Therapy, Personalized NeoAntigen Peptides, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dana-Farber Cancer Institute